And finally, our results revealed that CSF levels of 17β-HSD10–cypD complexes can be a very sensitive biomarker of AD including early disease stages (compare the very high sensitivity to MCI-AD 86.4% with that to ADD 92.9%). Here, HSD17B10 is linked to Alzheimer disease.